Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

SOX plus PD-1 inhibitor

SOX or XELOX plus PD-1 inhibitor

DRUG

PD-1 / PD-L1 monoclonal antibody

PD-1/PD-L1 monoclonal antibody

DRUG

SOX Chemotherapy

SOX or XELOX

DRUG

Tegafur-Ugotex or Capecitabine

All Listed Sponsors

lead

Liaoning Cancer Hospital & Institute

OTHER